Background Stenotrophomonas maltophilia has emerged as an important opportunistic
pathogen, causing infections whose management is often problematic due to its inherent …

Stenotrophomonas maltophilia (SM) represents a challenging pathogen due to its resistance
profile. A systematic review of the available evidence was conducted to evaluate the best …

Objectives The historical treatment of choice for Stenotrophomonas maltophilia infection is
trimethoprim/sulfamethoxazole and this is primarily based on preclinical studies. The …

Background Fluoroquinolones are a popular alternative to trimethoprim-sulfamethoxazole
for Stenotrophomonas maltophilia infections. Objectives To compare the effects of …

Stenotrophomonas maltophilia is a ubiquitous organism associated with opportunistic
infections. In the immunocompromised host, increasing prevalence and severity of illness is …

Introduction Stenotrophomonas maltophilia is a little-known environmental opportunistic
bacterium that can cause broad-spectrum infections. Despite the importance of this …

Stenotrophomonas maltophilia has emerged as an important nosocomial pathogen capable
of causing respiratory, bloodstream, and urinary infections. The treatment of nosocomial …

Objectives Stenotrophomonas maltophilia is a Gram-negative bacillus intermittently isolated
from hospitalized patients. Trimethoprim/sulfamethoxazole is considered the treatment of …

Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has
emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes …

The treatment of choice for Stenotrophomonas maltophilia is trimethoprim-sulfamethoxazole
(SXT). Fluoroquinolones (FQs) have in vitro activity against S. maltophilia; however, there is …